A team at IOCB Prague revealed a novel phase where liquids flip rapidly between metal and nonmetal states. The theory, based on advanced modeling, was featured in Nature Communications.

The scientific team of Dr. Pavel Majer from the IOCB of the CAS has developed a new substance with the potential to treat the autoimmune disease alopecia areata, which is manifested by hair loss.

Roman and Anton Bushuiev joined experts from 14 institutes in MassSpecGym, a project to benchmark AI methods for discovering natural molecules from MS, aiding drug development, ecology, and space research.

Dr. Tomáš Pluskal has been accepted into the prestigious ‘Young Investigator Programme’ of the EMBO and has also secured the ERC grant.

An important step in countering antibiotic resistance has been made by researchers from IOCB Prague, the Institute of Microbiology and the Institute of Biotechnology of the CAS.

IOCB Prague opened its new branch in Boston, USA on October 18, 2024. The move puts the institute in proximity to scientific institutions, such as Harvard University, MIT, and Boston Medical Center.

Researchers from IOCB Prague are furthering the understanding of how medicines work and what it takes to develop their most effective variants.

Even heavily modified double helices of DNA are stable enough to be used for special applications.

Scientists from Dr. Lenka Maletinska's team have developed a new substance that may help to solve the health limitations of obesity and Alzheimer's disease.

A research group led by Dr. Edward Curtis has developed two new types of catalytic DNA molecules (deoxyribozymes) that can reveal the presence of target molecules through fluorescence or color.